“Ozempic causes pancreatitis.”
What the evidence shows
Acute pancreatitis is a recognized, serious concern that GLP-1 labels flag: the prescribing information advises stopping the drug if pancreatitis is suspected. But whether the drugs actually cause it is not settled. A 2025 meta-analysis of randomized trials found a modestly raised signal (relative risk about 1.44), which weakened to non-significance once trials were sorted by background diabetes medication — meaning an independent effect of the GLP-1 itself is uncertain rather than proven. Real-world (FAERS) reports show pancreatitis clustering in the first months of use, and because these drugs do raise gallstone/biliary risk, a gallstone-driven (rather than direct) pathway is plausible.
What we still don’t know
We don't know whether the signal reflects a true direct effect, the drug's gallstone risk, or confounding (people with diabetes and obesity already have higher baseline pancreatitis risk). The absolute risk appears low, but the trials weren't individually powered for a rare event, so a small real effect can't be fully excluded.
Why the claim misleads
Stating "Ozempic causes pancreatitis" as fact promotes a labeled precaution and a weak, attenuating signal into proven causation. The honest read is a real, respected caution — new severe abdominal pain radiating to the back, with vomiting, is a reason to seek care and stop the drug — sitting alongside genuine uncertainty about whether the medicine is the cause. Caution warranted; case not closed.
Graded by The Peptide Era · evidence, not hype